Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessment of MGMT Promoter Methylation and Clinical Benefit From Temozolomide-based Therapy in Ewing Sarcoma Patients

NCT03542097 is registered in ClinicalTrials.gov with Istituto Ortopedico Rizzoli as lead sponsor.

NCT NCT03542097
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03542097 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessment of MGMT Promoter Methylation and Clinical Benefit From Temozolomide-based Therapy in Ewing Sarcoma Patients
Lead sponsor
Istituto Ortopedico Rizzoli
Phase
Observational
Overall status
Completed
Start date
April 15, 2014
Completion date
June 30, 2019
Enrollment
82 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

ewing sarcoma family of tumors